Clicky

Immunovant, Inc.(IMVT)

Description: Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It is developing IMVT-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.


Keywords: Medicine Biopharmaceutical Immune System Antibodies Autoimmune Disease Monoclonal Antibodies Eye Monoclonal Antibody Anemia Thyroid Eye Diseases Transfusion Medicine Treatment Of Autoimmune Disease Myasthenia Gravis Myasthenia Acquired Hemolytic Anemia Thyroid Eye Disease Treatment Of Myasthenia Gravis

Home Page: immunovant.com

IMVT Technical Analysis

320 West 37th Street
New York, NY 10018
United States
Phone: 917 580 3099


Officers

Name Title
Dr. Frank M. Torti M.B.A., M.D., MBA Exec. Chairperson of the Board
Dr. Peter Salzmann M.B.A., M.D. CEO & Director
Ms. Eva Renee Barnett M.B.A. Chief Financial Officer
Dr. William L. Macias M.D., Ph.D. Chief Medical Officer
Dr. Julia G. Butchko Ph.D. Chief Devel. & Technology Officer
Dr. Chau Cheng M.B.A., Ph.D. VP of Investor Relations
Mr. Mark S. Levine Chief Legal Officer & Corp. Sec.
Ms. Lauren Schrier M.B.A. VP of Marketing

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 4.7266
Price-to-Sales TTM: 0
IPO Date: 2019-06-21
Fiscal Year End: March
Full Time Employees: 124
Back to stocks